United Kingdom· GB-APID-46008911000001104
Exdensur 100mg/1ml solution for injection pre-filled pens
A depemokimab product containing depemokimab, registered in United Kingdom by GlaxoSmithKline UK Ltd. The same ATC class is registered in 9 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Depemokimab is registered in 9 of 19 countries.
Countries holding a registration under ATC R03DX12 (depemokimab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 5 of them publish a price we can compare per daily dose
Depemokimab · ATC R03DX12
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Depemokimab
- Manufacturer
- GlaxoSmithKline UK Ltd
- Country
- United Kingdom (GB)
- ATC code
- R03DX12
- ATC class
- Depemokimab
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin05054290013795
- gtin5054290013795
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Depemokimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandExdensurGlaxoSmithKline Trading Services Limited
- SwedenEXDENSUR 100 mg Injektionsvätska, lösning i förfylld injektionspennaGlaxoSmithKline Trading Services Ltd
- SpainEXDENSUR 100 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAGlaxosmithkline Trading Services Limited
- CzechiaEXDENSURGlaxoSmithKline Trading Services Limited, Dublin
- IcelandEXDENSURGlaxoSmithKline Trading Services Limited
- BelgiumExdensur 100 mgGlaxoSmithKline Trading Services
- United StatesExdensurGlaxoSmithKline LLC
- FinlandEXDENSURGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Exdensur
- Liechtenstein · Exdensur
- Norway · Exdensur
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d8163095-3ab5-4514-827a-db56a8342f0e GET /v1/drugs/d8163095-3ab5-4514-827a-db56a8342f0e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "46008911000001104",
"desc": "Exdensur 100mg/1ml solution for injection pre-filled pens (GlaxoSmithKline UK Ltd)",
"form": "Solution for injection",
"vpid": "46015311000001106",
"source": "dmd",
"vtm_id": "46013011000001107",
"strength": "100 mg",
"substance": "Depemokimab",
"ingredient": "Depemokimab",
"supplier_code": "4012301000001105"
}See everything about depemokimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.